The Tauranga arm of P3 Research has celebrated 10 years of success.
The Tauranga arm of P3 Research has celebrated 10 years of success.
The Tauranga arm of P3 Research, which performs clinical research trials for international pharmaceutical companies, this month celebrated its 10th anniversary in the Bay with an award from longtime global client INC Research.
"The INC Research award was given to us for the quality of the work we produce andhaving a clinical trials site dedicated to excellence," said P3's local research manager Katie Kennett, who runs the Tauranga site.
P3 Research was founded in Wellington in 1998, expanded into the Bay in 2005, and recently opened a site in Hawke's Bay.
"We perform clinical trials for international companies and contract research organisations and also undertake some clinical research for individual researchers," said Ms Kennett, a registered nurse who has been involved in clinical research for two decades.
The company is capable of performing a range of studies from small scale early Phase 2 trials to long-term Phase 3 studies and post-marketing investigations. P3 Research also performs research into issues such as patient compliance and the development of delivery devices. Before they can be licensed by international bodies such as the US Food and Drug Administration (FDA), new medications go through several stages of trials.
In Phase I trials, researchers test a new drug on a small group of people to evaluate safety, determine the dosage and identify side effects. In Phase 2 trials, the drug is given to a larger group to see if it is effective and further evaluate its safety. Phase 3 trials involve large group trials, comparisons to other treatments and further research into side effects. The award was for P3 Research's contribution to a major international migraine trial carried out by INC Research.
"P3 Research Tauranga has successfully screened and enrolled at the highest level for the migraine study across Australia and New Zealand," said Rayone Christante, who presented the award. David Porter
